Key takeaways:
Spravato (esketamine) is a ketamine-based nasal spray that’s FDA-approved to treat severe depression in adults. It’s given by a healthcare professional in a medical setting.
Common Spravato side effects include dissociation (feeling disconnected from your mind or body), drowsiness, and dizziness. More serious side effects include high blood pressure, slowed breathing, and misuse.
Most Spravato side effects are mild and short-lived. Your healthcare team will watch you closely for at least 2 hours after you receive your Spravato dose.
Depression can be a difficult experience. And if you or a loved one have tried multiple medications without relief, it’s even harder. In some cases, your medical care team may recommend something more than oral antidepressants alone.
Recently, ketamine infusions have been in the spotlight as a depression treatment option. But at this time, injectable ketamine isn’t FDA-approved for this use. Spravato (esketamine) is a ketamine-like medication that’s available as a nasal spray. It's the only FDA-approved ketamine-based treatment for severe or treatment-resistant depression, and it has to be given by a healthcare professional. Even though it’s been called a game-changer, there’s still some important Spravato side effects to consider.
Spravato was approved by the FDA in 2019. In initial clinical trials, as well as more recent studies of people receiving Spravato in the real world, recipients reported similar side effects.
Common/mild side effects include:
Sleepiness
Nausea and vomiting
Dissociation (feeling detached from reality)
Dizziness
Headache
Nose or throat irritation
Altered taste
Dry mouth
Diarrhea or constipation
Anxiety
Increased heart rate
Feeling of intoxication
Blurred vision
Numbness to touch
Rare but serious side effects include:
High blood pressure
Slowed breathing
Suicidal thoughts and behaviors
Hallucinations
Loss of consciousness
Dependence and misuse
In this article, we’ll talk more in-depth about nine of these Spravato side effects.
Good to know: You shouldn’t receive Spravato if you’re breastfeeding or planning to become pregnant. This can cause harm to your baby.
Dissociation — feeling disconnected from your mind or body — is a common Spravato side effect, especially after your first few doses. Symptoms tend to peak 30 to 40 minutes after receiving your dose and go away after 2 hours in most cases. The feeling is usually mild but can cause anxiety for some people. And in rare cases, more severe dissociation symptoms occur, including hallucinations.
A healthcare professional will watch you closely for at least 2 hours after each Spravato dose. Additionally, the following tips might help you during your appointment:
Engage in breathing and mindfulness exercises
Listen to calming music on your phone or other device
Ask your medical care team if a friend or family member can be with you for support
Dissociation rarely continues beyond 2 hours. Still, it’s possible to have lingering effects for a day or two. So plan on having a ride home after your Spravato dose. In fact, you should avoid any task that requires alertness for 24 hours.
Drowsiness after receiving Spravato is usually mild and goes away the same day. But if you take other medications that make you sleepy, drowsiness can worsen. Your healthcare provider may ask you to avoid sedating medications while you’re being treated with Spravato. Examples include benzodiazepines, opioids, and sleeping pills.
Plan on resting after you get home from your Spravato treatment. If you live alone, ask a friend or family member to check in on you. And if you still feel tired a day or two later, let your prescriber know.
Good to know: Spravato is typically prescribed along with oral antidepressants, many of which are known to cause drowsiness. So if tiredness from other medications is affecting your daily life, let your healthcare team know.
You might feel lightheaded after receiving Spravato. A spinning sensation (vertigo) can also occur. After receiving Spravato, lying down might help you cope with dizziness.
On days you receive Spravato, be careful when changing positions — such as standing up from a sitting position — and take it slow. Staying hydrated and eating regularly may help you feel better. Reach out to your provider if dizziness continues the next day or is severe. They may recommend a lower Spravato dose for your next treatment, since dizziness tends to be more likely with higher doses.
It’s common to feel a wave of nausea after receiving Spravato. Vomiting is less common but also possible. To lower the risk, stop eating at least 2 hours before (and drinking at least 30 minutes before) your Spravato dose.
Some medications, such as Zofran (ondansetron), may help treat nausea caused by Spravato. Or your prescriber may recommend taking it before your Spravato dose to prevent nausea.
Some people experience a foul or metallic taste in their mouth after receiving Spravato. This may be because the nasal spray can drain into your throat, leaving an aftertaste. Dry mouth, nasal discomfort, and throat irritation are also possible.
Masking the aftertaste with something fruit-flavored may help. Consider bringing your own flavored water or powdered drink mix packets to add to water, so you can drink something after your Spravato dose. If this doesn’t work, know that your mouth will likely feel normal by the end of the day.
Up to 20% of people may experience an increase in blood pressure after receiving Spravato. This could happen with any Spravato dose, even if you haven’t experienced it in the past.
Your healthcare team will check your blood pressure before and after each Spravato dose. For most people, blood pressure normalizes within 2 hours of a Spravato dose. But if you experience any serious symptoms when you get home, such as chest pain or shortness of breath, seek immediate medical attention.
Keep in mind: People with a history of heart problems may be more likely to experience blood pressure problems from Spravato. So make sure to share your complete health history with your prescriber before starting Spravato.
There have been some reports of serious breathing problems with Spravato. This is extremely rare, but your risk may be higher if you take other medications or use substances (such as alcohol) that can slow breathing. Giving your prescriber a list of all your medications will help them check for interactions. And let your prescriber know if you drink alcohol, which can also contribute to slowed breathing (and worsen depression).
The risk of slowed breathing from Spravato is part of the reason you’ll stay at your prescriber’s office for at least 2 hours after receiving your dose. During this time, your oxygen levels will be monitored. Your medical team will let you know when it’s safe to go home. But let them know right away if you feel like you can’t stay awake or you’re going to pass out.
Spravato is approved for people with depression who are having suicidal thoughts or behaviors. But in rare cases, people have experienced worsening depression or thoughts of suicide while receiving Spravato.
This side effect isn’t common. But it’s a good idea to have a plan in place in case it happens. Consider the following tips:
Arrange for frequent check-ins with your support system (such as family, friends, and healthcare professionals).
Discuss other treatment options with your provider if Spravato hasn’t helped after 4 weeks of treatment.
Be watchful for worsening depression and mood changes
If you or someone you know is having thoughts of suicide, you’re not alone, and help is available. Call the 988 Suicide & Crisis Lifeline at 988, or text HOME to 741-741 to reach the Crisis Text Line.
Spravato is a controlled substance. This means it has a risk for dependence and misuse. Because of this (and the risk of dissociation and trouble breathing), it’s only given in a healthcare professional’s office. And both you and your prescriber must enroll in Spravato’s Risk Evaluation and Mitigation Strategy (REMS) program before you can receive it. This is a drug safety program required by the FDA to manage the risks of certain medications.
Spravato misuse is unlikely to be an issue if you’re receiving Spravato as recommended under your healthcare team’s supervision. Misuse is more likely if you’re using non-FDA-approved compounded nasal sprays or if you’re administering Spravato yourself at home. You should only receive Spravato that’s FDA-approved and administered by a healthcare professional. Misuse is also more likely if you have a history of substance use disorder.
If you or someone you know struggles with substance use, help is available. Call SAMHSA’s National Helpline at 1-800-662-4357 to learn about resources in your area.
Most Spravato side effects go away within 2 hours of receiving your dose. And since you’ll be in your prescriber’s office during that time, you can alert your care team about any side effects.
But if you experience any Spravato side effects that continue into the following day, let your healthcare team know. And if you notice any of the following severe symptoms, seek emergency care:
Severe mood changes
Chest pain
Trouble breathing
Hallucinations
Suicidal thoughts or actions
Common Spravato (esketamine) side effects include dissociation (feeling disconnected from mind or body), drowsiness, and dizziness. You may also experience nausea and vomiting, altered taste, or a temporary increase in blood pressure. More serious Spravato side effects include breathing problems, suicidal thoughts and behaviors, and misuse.
You’ll be monitored at your prescriber’s office for at least 2 hours after receiving your Spravato dose. Most side effects should resolve within this timeframe. Still, avoid driving and other tasks that require attention until the day after receiving your dose. And let your care team know if you notice any lingering side effects. If you experience any severe symptoms, such as chest pain, trouble breathing, or severe mood changes, seek emergency care.
Anderson, P. (2019). FDA's rapid approval of esketamine for severe depression questioned. Medscape.
Bahr, R., et al. (2019). Intranasal esketamine (Spravato) for use in treatment-resistant depression in conjunction with an oral antidepressant. Pharmacy and Therapeutics.
Ballard, E. D., et al. (2020). The role of dissociation in ketamine’s antidepressant effects. Nature Communications.
Bell, F. (2023). Acute suicidal ideation in the context of esketamine maintenance therapy. The American Journal of Psychiatry.
Bossaller, N. A., et al. (2020). Real-world approach to managing dysgeusia following the use of esketamine nasal spray: A case report. Annals of General Psychiatry.
Boudieu, L., et al. (2023). The efficacy and safety of intranasal formulations of ketamine and esketamine for the treatment of major depressive disorder: A systematic review. Pharmaceutics.
Doherty, T., et al. (2020). Cardiac safety of esketamine nasal spray in treatment-resistant depression: Results from the clinical development program. CNS Drugs.
Guo, H., et al. (2022). Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Frontiers in Pharmacology.
Janssen Pharmaceuticals, Inc. (n.d.). Spravato REMS (Risk Evaluation and Mitigation Strategy).
Janssen Pharmaceuticals Inc. (2023). Spravato- esketamine hydrochloride solution [package insert].
McIntyre, R. S., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry.
McIntyre, R. S., et al. (2023). Treatment‐resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry.
U.S. Food & Drug Administration. (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic.
U.S. Food & Drug Administration. (2022). FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray.
U.S. Food & Drug Administration. (2023). Drug safety-related labeling changes (SrLC).
Williamson, D., et al. (2023). Adverse events and measurement of dissociation after the first dose of esketamine in patients with TRD. International Journal of Neuropsychopharmacology.
Zaki, N., et al. (2023). Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: Interim results of the SUSTAIN-3 study. Neuropsychopharmacology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.